13 May 2020
Riber’s Q1 revenue down 19% year-on-year
For first-quarter 2020, Riber S.A. of Bezons, France – which manufactures molecular beam epitaxy (MBE) systems as well as evaporation sources and effusion cells – has reported revenue of €5.3m (62% from Europe, 34% from Asia and just 4% from the USA). This is down 19% on €6.6m a year ago (of which only 30.1% came from Europe, 32.3% came from Asia, and as much as 37.6% came from the USA).
Revenue for MBE systems was €2.3m, down 44% on €4.1m a year ago. This includes billing for just one production system, compared with two a year ago. Difficulties related to export licenses led to a delay in the billing of a research system in Q2/2020.
Revenues for Services & Accessories grew strongly by 79% from €1.7m to €3m.
In line with previous quarters (and just €0.8m a year ago), revenue for Evaporators (cells and sources) is negligible due to the lack of investment in the organic light-emitting diode (OLED) screen industry.
The order book at the end of March was down 18% from €32.2m a year ago to €26.5m. Due to the difficulties of finalizing contracts in Asia linked to the pandemic, MBE system orders are down by 25% from €25.3m to €18.9m (comprising 11 systems to be delivered in 2020, including three production units). Orders for Services and accessories are up 11% from €6.8m to €7.6m. Evaporators orders were zero, compared with just €0.1m a year ago.
In the context of the Covid-19 coronavirus pandemic, Riber says it has adapted its organization to minimize the impact of the health crisis on its business. Due to the actions rolled out since 13 March, Riber has been able to keep almost all its staff operational, working either from home or on site. More specifically, it is still able to produce and deliver, while continuing to develop its strategic projects. However, the firm faces a slowdown in its commercial activity, with certain orders deferred, especially in China (Riber’s leading region), where the 5G market is still very buoyant.